David Allan was the founding and sunset chairman, and the CEO from 1998 to 2011, of YM BioSciences Inc. until its acquisition by Gilead Sciences in 2013.

He has been a board member of a number of life sciences companies and was Executive Chairman of Stem Cell Therapeutics concluding its acquisition of Trillium Therapeutics which name it has now adopted.

He is currently the Principal of Cresswell Advisors,  a consulting firm that provides assistance and direction to development-stage companies in the life sciences and for earlier-stage companies  in  multiple fields.

 

He is also a board member of Formation Biologics, of the industry organization Life Sciences Ontario, and of the Maple Leaf Angels Capital Corporation

Previously a Governor of the Toronto Stock Exchange, he has been a member of the Ontario Biotechnology Advisory Board, the Awards Selection Committee of Canada's Network of Centers of Excellence and the Multidisciplinary Assessment Committee of the Canada Foundation for Innovation.

He is the recipient of the 2017 Julia Levy Award recognizing successful commercialization of innovation in the field of Bio-medical Science and Engineering,  the 2016 Leadership Award from Life Sciences Ontario and the 2012 Gold Leaf Award for Industry Leadership from Canada's industry association BIOTECanada.
 

David Allan

Cuban Biotechnology
Cresswell Advisors